• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MannKind Corporation - Common Stock (NQ:MNKD)

    2.810 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,805
    Open 2.810
    Bid (Size) 2.790 (2,600)
    Ask (Size) 2.840 (5,000)
    Prev. Close 2.810
    Today's Range 2.810 - 2.810
    52wk Range 2.230 - 6.510
    Shares Outstanding 264,305,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
    From MannKind
    Via GlobeNewswire

    Performance

    YTD
    -49.8%
    -49.8%
    1 Month
    +12.4%
    +12.4%
    3 Month
    -53.2%
    -53.2%
    6 Month
    -48.7%
    -48.7%
    1 Year
    -43.8%
    -43.8%

    More News

    Read More
    News headline image
    MannKind Announces Settlement of Convertible Senior Notes
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Participate in Upcoming Investor Conferences
    From MannKind
    Via GlobeNewswire
    MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 ↗
    Via Chartmill
    MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
    Via Stocktwits
    MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
    Via Stocktwits
    News headline image
    What's Going On With MannKind Stock Friday? ↗
    Via Benzinga
    News headline image
    Why MannKind Stock Tumbled on Thursday ↗
    Via The Motley Fool
    News headline image
    MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From MannKind
    Via GlobeNewswire
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
    Via Stocktwits
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
    From MannKind
    Via GlobeNewswire
    News headline image
    MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
    From MannKind
    Via GlobeNewswire
    News headline image
    Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
    From MannKind
    Via GlobeNewswire
    News headline image
    Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
    From Equity Insider
    Via GlobeNewswire
    News headline image
    MannKind Provides Business Updates and 2026 Growth Drivers
    From MannKind
    Via GlobeNewswire
    News headline image
    Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    MannKind Shares FUROSCIX® Business Updates
    From MannKind
    Via GlobeNewswire

    Frequently Asked Questions

    Is MannKind Corporation - Common Stock publicly traded?
    Yes, MannKind Corporation - Common Stock is publicly traded.
    What exchange does MannKind Corporation - Common Stock trade on?
    MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MannKind Corporation - Common Stock?
    The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
    What is the current price of MannKind Corporation - Common Stock?
    The current price of MannKind Corporation - Common Stock is 2.810
    When was MannKind Corporation - Common Stock last traded?
    The last trade of MannKind Corporation - Common Stock was at 05/04/26 04:00 PM ET
    What is the market capitalization of MannKind Corporation - Common Stock?
    The market capitalization of MannKind Corporation - Common Stock is 742.70M
    How many shares of MannKind Corporation - Common Stock are outstanding?
    MannKind Corporation - Common Stock has 743M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.